

For discussion

On 18 December 2012

Legislative Council Panel on Commerce and Industry
Research and Development of Chinese Medicines

PURPOSE

This paper updates Members on the progress of effort made in promoting research and development (R&D) of Chinese medicines (CM).

BACKGROUND

2. By virtue of its culture, geographic location, and acceptance of CM, Hong Kong has developed a well-established CM market over the years. Together with Hong Kong's strengths in scientific research, product testing, etc., Hong Kong has the edge to further promote the development of CM.

3. Following a comprehensive review in 2010/2011 on how best to support R&D and testing of CM, the Committee on Research and Development of Chinese Medicines (the Committee) was established to facilitate collection of views from stakeholders and better coordinate effort in promoting R&D and testing of CM to meet the future needs of Hong Kong. The Committee is chaired by the Commissioner for Innovation and Technology and comprises representatives from the Government, industry, academic and research sectors. Membership and ----- the terms of reference of the Committee are at *Annex 1*.

4. The Committee has adopted the following broad directions to promote the development of the CM sector in Hong Kong:

- (A) strengthen support for R&D of CM;
- (B) promote testing and certification of CM;
- (C) facilitate collaboration among stakeholders;
- (D) understand and support industry needs; and
- (E) promote the work of the Committee to the industry and the community.

More details are provided in the paragraphs below.

(A) STRENGTHEN SUPPORT FOR R&D OF CM

5. In late 1999, Government set up the \$5 billion Innovation and Technology Fund (ITF) to fund applied R&D projects of various technology areas including CM. Through the ITF, Government provides funding support for the development of modern technology platforms and procurement of advanced equipment for local universities and research institutions to enhance their capabilities. Since its establishment, the ITF has supported over 70 CM-related projects with a total funding of about \$170 million. The nature of these projects includes new CM development, technologies related to CM manufacturing and quality control (QC), pre-clinical and clinical evaluation of CM, as well as integrative Chinese and Western medicines. Project applications were assessed on various fronts, including scientific component, technical and management capability of the research team, proposed budget, etc. The ITF has also assisted the establishment of many R&D facilities, such as the Process Development Facility for CM in the Hong Kong Institute of Biotechnology (HKIB), the Traditional Chinese Medicine Centre of the Biotechnology Research Institute in The Hong Kong University of Science and Technology, and the Quality Research Laboratory of Hong Kong Baptist University. These establishments can provide service and support that are of high standards to the CM industry.

6. Apart from the ITF, The Hong Kong Jockey Club Charities Trust (HKJCCT) has also pledged \$500 million funding support for CM R&D in 2001. A total of 18 projects with a total funding amount of \$108 million were supported over the last 10 years via the Hong Kong Jockey Club Institute of Chinese Medicine (HKJCICM). Upon the announcement of the disbandment of the latter in 2011, HKJCCT has agreed to use the residual \$400 million funding to support non-profit organisations in carrying out worthwhile CM projects in Hong Kong.

7. In Hong Kong, most of the CM R&D are conducted by or in partnership with local universities. In the past months, representatives from these universities have been invited to present their CM-related activities to the Committee to give all Members an overview of the local CM R&D (apart from universities, relevant organisations such as the Hong Kong Council for Testing and Certification (HKCTC) and the HKIB were invited to present to the Committee). The Committee noted their enthusiasm and effort and encouraged them to make good use of the ITF to support evidence-based CM R&D projects, especially in areas which CM has advantages (e.g. chronic diseases) and Hong Kong has strengths. A special theme on R&D of CM was then included in the second round of invitation of proposals under the Innovation and Technology Support Programme in 2012. A total of more than 20 proposals covering various research areas such as R&D of evidence-based CM formulas and new CM, QC technologies for CM manufacturing, CM R&D platform development, and integrative

medicine have been received and are currently being assessed.

8. As the "meeting point" of the East and West and with excellence in Western medicine practice, Hong Kong carries particular advantages in promoting R&D of integrative Chinese and Western medicines. The Innovation and Technology Commission (ITC) encourages universities to explore the best that can be done on this front and submit R&D proposals to the ITF.

(B) PROMOTE TESTING AND CERTIFICATION OF CM

9. Testing and certification has been identified as one of six economic areas where Hong Kong enjoys clear advantages and has good potential for further development. In September 2009, HKCTC was established to advise Government on the overall development strategy and initiatives for promoting the growth of the industry.

10. In April 2010, Government accepted HKCTC's three-year market-oriented development plan for the testing and certification industry, which recommended a dual approach – making general improvements to the accreditation service and factors of production of the industry, whilst putting focused efforts on specific trades with particular potentials. CM is one of the specific trades considered by HKCTC to have great potentials to generate demand for testing and certification

services.

11. Laboratories in Hong Kong have been providing testing services for Chinese materia medica and registration of proprietary CM (pCm), e.g. testing for heavy metals and toxic elements, pesticide residues, microbiological examinations and chemical stability. HKCTC has set up a Panel comprising members from the CM trade, the testing and certification industry, academia, relevant Government departments and public bodies to provide a cooperation platform for stakeholders to develop and promote new CM testing and certification services.

Developing New Testing and Certification Services

12. Under the management and coordination of Department of Health (DH), Hong Kong has been developing the Hong Kong Chinese Materia Medica Standards (HKCMMS). HKCMMS are good references for testing laboratories in providing authentication services for Chinese materia medica. HKCTC's CM Panel helps testing laboratories to enhance their technical capability in carrying out testing based on HKCMMS –

- (a) a proficiency testing programme for testing laboratories was organised from April to June 2012. The proficiency testing programme is an inter-laboratory comparison exercise for testing laboratories to assess their technical

capability in conducting chemical testing for CM and to identify areas for improvement. Twelve local laboratories participated and their consistent results reinforced confidence in local laboratories' technical competence; and

- (b) a training course on authentication of CM by microscopic inspection for the practitioners was organised from April to August 2012. The course was organised to meet the demand from the testing and certification industry in view of the shortage of people with the required skills in microscopic inspection in the market.

Both initiatives have assisted testing laboratories in meeting requirements when seeking accreditation from Hong Kong Accreditation Service (HKAS). HKAS has started to receive accreditation applications for CM testing according to HKCMMS. One laboratory has just been granted accreditation for identification of two Chinese materia medica *viz.* *Radix Ginseng* (人參) and *Radix Panacis Quinquefolii* (西洋參) by chemical and physicochemical techniques according to HKCMMS.

13. Separately, HKCTC's CM Panel supports the Hong Kong Productivity Council in developing a product certification scheme for Chinese materia medica. The project was funded by the General Support Programme of the ITF. The product certification scheme aims to provide enhanced quality assurance and will provide traders and

suppliers an effective means to demonstrate product quality. Accredited certification bodies will be allowed to provide certification services based on the scheme, which will also generate new demand for CM testing. Development work commenced in June 2012 with a pilot run planned for early 2013.

Promotion of Testing and Certification Services

14. A seminar was organised in July 2012 to introduce authentication services to the CM trade. Experts from university, DH, Government Laboratory and the Customs and Excise Department and the CM trade shared the latest development in HKCMMS, technical know-how in authentication and the potential needs from the angle of CM trade and consumer protection.

15. To promote Hong Kong's testing services to traders of CM, HKCTC and HKAS jointly set up a promotional booth in the annual International Conference and Exhibition of the Modernization of Chinese Medicine and Health Products in both 2011 and 2012. Some examples
----- of the relevant promotion materials are at Annex 2.

(C) FACILITATE COLLABORATION AMONG STAKEHOLDERS

16. To facilitate collaboration among the Government, industry, academic and research sectors, and to encourage sharing of knowledge on R&D of CM, a one-day seminar on Chinese medicines was organised by the Committee on 14 September 2012.

17. The seminar covered a variety of topics on CM, including the regulatory mechanism on CM in Hong Kong, clinical trials, local and regional collaboration on R&D of CM, and testing and certification of CM. Some eminent speakers of the seminar included Professor Joseph Sung, Vice-Chancellor and President of The Chinese University of Hong Kong; Professor So Kwok-fai, Chair Professor of Department of Anatomy of The University of Hong Kong; Professor Lu Aiping, Dean of the School of Chinese Medicine of Hong Kong Baptist University; Professor Tang Xudong, Director of Xi Yuan Hospital of China Academy of Chinese Medical Sciences; and Professor Liu Liang, Vice Rector (Research and Development) of Macau University of Science and Technology. The seminar programme is at Annex 3. More than 400 representatives from the Government, industry, academic and research sectors attended the event. The seminar was well received by participants who considered it to be a very useful platform for different stakeholders in the CM sector to exchange ideas and update their knowledge on CM R&D in Hong Kong. It is suggested that a similar event be organised next year.

(D) UNDERSTAND AND SUPPORT INDUSTRY NEEDS

R&D Infrastructure for the Industry

18. As for infrastructure, the Hong Kong Science Park (HKSP) managed by the Hong Kong Science and Technology Parks Corporation provides R&D infrastructure, including two laboratory buildings with central facilities in HKSP Phase Two, which can support companies in the Park engaging in R&D of CM. The HKSP also has an “Incu-Bio Programme” which can assist start-up technology companies with subsidized rent, and various supporting services such as business development support, collaboration with university and industry, training, technology support facilities, etc. The CM community at the HKSP has recently been further enriched by the establishment of two CM research laboratories by Hong Kong Baptist University and the Chinese Medicines Section of the Government Laboratory. The biotechnology industry (including CM and western pharmaceuticals) will be one of the focuses in promoting HKSP Phase Three development, which is expected to be completed in stages from 2014 onwards.

Chemical Markers and Development of Methods of Analysis

19. In meeting the regulatory requirements of pCm registration, manufacturers are required to submit technical information and test

reports, including methods of analysis for QC and stability studies of the products. Some local manufacturers lack the expertise to develop the necessary analytical methods while some of the chemical markers required for such analysis are not readily available locally.

20. In April 2012, on behalf of HKJCCT, ITC conducted a proposal invitation exercise to identify suitable parties to establish and operate a R&D laboratory for CM testing and provision of chemical markers to address the industry's demand. A joint research team formed by The Hong Kong University of Science and Technology and The University of Hong Kong was awarded \$5 million funding support from HKJCCT, together with the laboratory equipment and inventory of chemicals previously owned by HKJCICM, to carry out a two-year project on CM R&D and provision of chemical markers. In addition, HKJCCT committed another \$2 million funding support to Hong Kong Baptist University to conduct a two-year project focusing on CM testing and related support services for the CM industry. It is envisaged that collective efforts of the universities in these 2 projects would help to provide the required technical support to the CM industry.

Working Group on Chinese Medicines Manufacturing

21. At present, the Good Manufacturing Practice (GMP) requirement in respect of pCm in Hong Kong is not mandatory. Manufacturers holding a pCm manufacturer licence may

apply to the Chinese Medicines Board under the Chinese Medicine Council of Hong Kong for a Certificate for Manufacturer, certifying that they follow the requirements of good practices in manufacture and QC of pCm. To date, there are ten pCm manufacturers who have been awarded GMP Certificates. To ensure the quality and safety of pCm, it was announced in the 2010-11 Policy Address that a timetable for mandatory compliance with GMP for manufacture of pCm would be worked out, to keep up with international trends of developing GMP for medicines.

22. The Committee has discussed the future mandatory requirements of pCm GMP and the difficulties that local manufacturers might face. It is noted that financial constraints, limitation of relevant expertise and suitable land space for establishing GMP facilities, as well as the timetable of Government to introduce the mandatory GMP requirements are among the major concerns of local pCm manufacturers. While the Food and Health Bureau/DH are responsible for the regulatory side and implementation of pCm GMP in Hong Kong, the Committee hopes to play a supportive role in facilitating the industry to upgrade and meet the various challenges ahead.

23. Noting that GMP is a complicated issue, and various regulatory- and non-regulatory-related factors would affect its implementation, the Committee has formed the “Working Group on Chinese Medicines Manufacturing” (the Working Group) to discuss the subject in greater detail, as well as other important R&D and technical

aspects of CM manufacturing which would facilitate industry upgrading in the long run.

24. The Working Group has held 2 meetings with particular focus on understanding the technology needs of the CM industry in GMP implementation. The Working Group generally agrees that many local manufacturers lack proper understanding of GMP, which is one of the factors deterring them from setting up GMP production. The Working Group recommends that relevant training in a systematic manner should be organised to help local pCm manufacturers get prepared for the future implementation of mandatory GMP requirements. The Working Group also suggests that there should be different types of training activities, in terms of content, duration and format, for different target groups, such as top management, middle management and front-line staff, according to their skill levels and roles in the companies. To follow up these suggestions, ITC is currently in discussion with GMP consultants (e.g. the HKIB) to organise appropriate training activities which would suit the needs of different levels of persons in the industry.

25. The Committee is also aware of the concerns of the industry for hardware support for GMP, especially for small and medium enterprises that lack the financial strength and expertise to support the building of GMP facilities and their subsequent operation. In this connection, the Committee is considering the possibility/options of GMP consultancy service and contract manufacturing arrangements. In

particular, it is in discussion with the HKIB to understand its present CM contract manufacturing services and whether its GMP facilities can be expanded to help address the increasing demand of the industry for pCm GMP manufacturing (Note: The HKIB, located in The Chinese University of Hong Kong (CUHK) campus in Shatin, New Territories, is a Company Limited by Guarantee wholly controlled by the Council of CUHK. It has been offering GMP consultation services to the pharmaceutical industry and has a GMP-complied production facility which can offer contract CM manufacturing services to local companies). Since local CM manufacturers vary widely in their technical knowledge and scale of operation, the Committee and ITC need to examine the overall potential demand, the size and needs of each subsector, etc., in conjunction with relevant stakeholders for better planning of the support to the industry on this front.

(E) PROMOTE THE WORK OF THE COMMITTEE TO THE INDUSTRY AND THE COMMUNITY

Advertorial Series on CM

26. In order to raise the profile of CM and give the public a better understanding of the latest development of CM R&D in Hong Kong, advertorials which included interviews of representatives from DH, HKCTC, local universities and the CM industry, were published in major

local newspapers. Some examples of these advertorials are enclosed at

----- *Annex 4.*

Radio Programme Series on CM

27. In addition, ITC has collaborated with the Radio Television Hong Kong to produce a radio programme series on CM. The programme consists of twenty 30-minute episodes with expert guest speakers coming from Government, public bodies, local universities and research institutions. The speakers have shared their knowledge on modernisation of CM, CM R&D activities conducted in local universities, the work of different CM-related organisations, and various CM topics that are of interest to the general public. The radio programme series commenced on 22 October 2012 and Dr Ko Wing-man, Secretary for Food and Health, was featured as the guest speaker of the first episode.

RELATED DEVELOPMENT

28. The Chief Executive has committed in his Election Manifesto to establish a Chinese Medicine Development Committee (the Development Committee), to present proposals to the Government concerning the strategy for the future development of Chinese medicine in Hong Kong. A Preparatory Task Force, chaired by Secretary for Food and Health has been established in mid-August to advise the Government

on the composition, terms of reference and focused areas of work of the Development Committee. As R&D and technology upgrading are important elements in the overall development of CM, the Committee on Research and Development of Chinese Medicines together with ITC will render full support to the new Committee when it is established.

ADVICE SOUGHT

29. Members are invited to note Government's latest effort in promotion of R&D of CM in Hong Kong.

Innovation and Technology Commission

December 2012

**COMMITTEE ON RESEARCH AND DEVELOPMENT
OF CHINESE MEDICINES**

Membership List

Chairperson

Commissioner for Innovation and Technology

Ex-officio

Director of Health or representative

Representative of the Hospital Authority

Representative of the Hong Kong Council for Testing and Certification

Representative of the Hong Kong Science and Technology Parks Corporation

Representative of the Hong Kong Jockey Club

Ad personam

Mr. AU Wai-hung, Anthony, BBS

Mrs. CHENG CHO Chi-on, Mariana, BBS, JP

Mrs. CHIN Hang-yin, Alice

Prof. IP Yuk-yu, Nancy, MH

Prof. LEE Sum-ping

Prof. LEUNG Ping-chung, SBS, OBE, JP

Mr. LI Ying-sang, Tommy, BBS, MH, JP

Prof. LIU Liang

Prof. LU Aiping

Ms. TANG Mui-fun, Karen

Mr. TSANG Chiu-hing

Mr. WONG Kong-hui, Kenlay, MH

Prof. WONG Ngar-kok, James, MH

Ms. WONG Suet-ying, Alice

Mrs. YIP CHIU Kwai-fong, Florence

Terms of Reference

The terms of reference of Committee on Research and Development of Chinese Medicines are : -

- (a) To act as a platform to gauge views from various stakeholders, including Government, public bodies, industry and the academia on the research and development of Chinese medicines in Hong Kong;
- (b) To formulate the broad direction in promoting research and development of Chinese medicines in Hong Kong, to identify key areas of work, monitor progress and recommend areas of improvement where necessary; and
- (c) To facilitate sharing of research and development outcome and other collaboration among parties concerned to create synergy in research and development of Chinese medicines and to promote collaboration with organisations outside Hong Kong.

主辦機構 Organizers

香港檢測和認證局
Hong Kong Council for
Testing and Certification

 香港認可處
Hong Kong
Accreditation Service

中藥真偽鑑定研討會

Seminar on Authentication of Chinese Medicines



2012年7月10日 (星期二)
下午2時15分至5時30分

10 July 2012 (Tuesday)
2:15pm to 5:30pm



支持機構 Supporting Organizations

 Hong Kong Association for Testing,
Inspection and Certification Limited
香港測檢認證協會有限公司

 香港中藥聯商會
HONG KONG CHINESE MEDICINE
MERCHANTS ASSOCIATION

 香港中藥業協會

 香港中成藥商會有限公司
HONG KONG CHINESE PREPARED MEDICINE
TRADERS ASSOCIATION LIMITED

 Hong Kong
Productivity Council
香港生產力促進局

 MCMIA
現代化中醫藥國際協會

 VTC



概要 Overview

香港是一個主要的中藥貿易中心。但如何鑑別中藥材？衛生署已製定了四期涵蓋96種中藥材的《香港中藥材標準》（《港標》），並計劃在2012年擴展到200種。香港實驗所/公證行可按《港標》以顯微鑑別及理化方法進行真偽鑑定，有助保障你的中藥材貨品為真品。

本研討會旨在讓檢測和認證業及中藥行業瞭解更多關於按《港標》進行的中藥真偽鑑定技術。來自大學和政府化驗所的專家會為大家介紹有關的技術，而中藥業界代表和香港海關則會分享對真偽測試的需求和它們如何有助政府的執法行動。

Hong Kong has been a major trading centre for Chinese medicines. How do we determine that the Chinese medicines are genuine? The Department of Health has published 4 phases of the Hong Kong Chinese Materia Medica Standards (HKCMMS) to cover 96 Chinese Materia Medica (CMM), which will be extended to cover 200 CMM in 2012. Hong Kong's testing laboratories can conduct authentication testing of CMM by microscopic identification and physicochemical methods. This authenticity testing of CMM could help to ensure that your Chinese medicines are genuine.

The Seminar aims to let the testing and certification industry and the Chinese medicines trade know more about authentication testing based on HKCMMS. Speakers from universities and the Government Laboratory will introduce the testing techniques. Representatives from the Chinese medicines trade and the Customs and Excise Department will share their views on the demand for the testing and how it could assist in law enforcement.

研討會詳情 Seminar Details

| | | |
|---|---|--|
| <p>地點 Venue</p> | <p>九龍塘達之路78號 生產力大樓4樓會議廳 Conference Hall, 4/F, HKPC Building, 78 Tat Chee Ave, Kowloon Tong</p> | |
| <p>日期 Date</p> | <p>2012年7月10日（星期二） 10 July 2012 (Tuesday)</p> | |
| <p>時間 Time</p> | <p>下午2時15分至5時30分 2:15pm to 5:30pm</p> | |
| <p>研討會主要對象 Target Audience</p> | <p>中藥行業及檢測和認證業從業員，以及對中藥真偽鑑定有興趣人士 Practitioners of Chinese medicines as well as the testing and certification industry; general public interested in authentication of Chinese medicines</p> | |
| <p>費用 Fee</p> | <p>免費入場 Free Admission</p> | |
| <p>語言 Language</p> | <p>廣東話及普通話 Cantonese and Putonghua</p> | |

程序表 Programme

| 由 From | 至 To | 程序 Programme |
|-----------|---------|---|
| 2:15 | 2:30 pm | 接待及登記 Reception and Registration |
| 2:30 | 2:40 pm | 歡迎辭 Welcoming Remarks 香港檢測和認證局推動中藥行業檢測和認證服務小組召集人 賴福明醫生 Dr Lawrence LAI, Convener of the Panel on Promoting Testing and Certification Services in Chinese Medicines Trade |
| 2:40 | 2:50 pm | 致送紀念品予講者嘉賓 Presentation of souvenirs to speakers |
| 2:50 | 3:10 pm | 發展《香港中藥材標準》 Development of Hong Kong Chinese Materia Medica Standards (HKCMMS) 衛生署 高級藥劑師(中醫藥) 羅國偉先生 Mr. LAW Kwok Wai, Senior Pharmacist (Traditional Chinese Medicine), Department of Health |
| 3:10 | 3:30 pm | 利用化學測試鑒別中藥材 Identification of Chinese Materia Medica by Chemical Testing 政府化驗所高級化驗師(藥品質量及檢驗組) 吳志成先生 Mr. NG Chi Shing, Senior Chemist (Pharmaceutical Quality & Investigation Sec), Government Laboratory |
| 3:30 | 3:50 pm | 顯微鑒別在中藥材真偽鑑定上的應用 Use of Microscopic Identification in the Authentication of Chinese Medicines 香港浸會大學中醫藥學院副院長 趙中振教授 Professor ZHAO Zhongzhen, Associate Dean, School of Chinese Medicine Hong Kong Baptist University |
| 3:50 | 4:10 pm | 答問環節 Q&A Discussions |
| 4:10 | 4:30 pm | 小休 Break |
| 4:30 | 4:40 pm | 中藥材真偽鑑定方面的需要 The Need for Authentication of Chinese Medicines 香港中藥業協會理事長李應生先生 BBS, MH, JP Mr Tommy Y S LI, BBS, MH, JP, Hong Kong Chinese Medicine Industry Association |
| 4:40 | 5:00 pm | 中藥鑑定檢測對香港海關在執行《商品說明條例》工作的重要性 The need of Authentication Test of Chinese Medicine in the Enforcement of Trade Descriptions Ordinance 香港海關 消費者保障科 高級調查主任 趙淑儀女士 Ms CHIU Shuk-ye, Senior Investigator, Consumer Protection Bureau, Customs and Excise Department |
| 5:00 | 5:20 pm | 中藥測試及鑒別的相關認可服務 Accreditation Services for Testing and Identification of Chinese Medicines 香港認可處高級認可主任 何振華博士 Dr. John HO, Senior Accreditation Officer, Hong Kong Accreditation Service |
| 5:20 | 5:30 pm | 答問環節 Q&A Discussions |
| 5:30 pm | | 結束 Ends |



報名辦法 Enrolment

請於2012年7月6日或之前，填妥報名表格，並以傳真或電郵交回：

To enrol, please complete the Enrolment Form and return it by fax or email on or before **6 July 2012**:

傳真 Fax : 2590 0099 或 or

電郵 Email : seminar-hkctc@swiretravel.com

研討會座位供應須視乎情況，我們將以電話或電郵在2012年7月7至9日間回覆作實。

Seats are subject to availability. Confirmation of seats available or otherwise will be made by phone or email between 7-9 July 2012.

報名表格 Enrolment Form

請為下列代表預留座位：

Please reserve a seat/seats for the following representative(s):

| | |
|---------------------------|--|
| 姓名 Name | |
| 職位 Position | |
| 機構名稱 Name of Organization | |
| 電郵 Email address | |
| 電話 Tel | |

(註：主辦機構聘請了太古旅遊作為代理機構協助籌備研討會，包括處理行政和報名等事宜。

Note: The seminar organizers have engaged Swire Travel Ltd as the event co-ordinator for the seminar to handle logistics and all enrolment matters.)

查詢 Enquiries

電話 Tel : 3151 8900 (黃小姐或鍾小姐 Ms Mavis Wong or Ms Vicky Chung)

電郵 Email : seminar-hkctc@swiretravel.com

注意事項 Important Notes

- (1) 報名表格將於研討會舉行後一個月內銷毀。
The Enrolment Form will be destroyed within one month after the seminar is held.
- (2) 提交報名表格後，如欲更改或查詢個人資料，請按上述查詢辦法提出。
For correction of or access to personal data after submission of the Enrolment Form, please contact the event co-ordinator under Enquiries above.
- (3) 參加者在本報名表格內所提供的個人資料，將用於研討會報名以及其他與研討會有關的事宜上。主辦機構及代理機構均會取得這些個人資料。
The personal data provided in this form will be used for enrolment to the seminar and other seminar-related purposes. The seminar organizers and the event co-ordinator will be able to access such personal data.
- (4) 如果你希望取得香港檢測和認證局日後舉辦的研討會或活動資料，請於右邊方格內打✓。
If you would like to receive information on future seminars or activities organized by HKCTC, please insert a ✓ in the box on right.



中藥測試的好處 Benefits of Chinese medicines testing

香港是一個主要的中藥國際貿易中心，2010年中藥材進口及轉口貨值分別達20億及8.6億港元。在香港銷售的中藥材一般都具有良好的質量。為確保產品是真的和沒有處理不當(例如漂白)，以及沒有摻雜其他成份和受污染，檢測和認證是一個重要的方法，而香港則擁有一個具備效率和先進技術的檢測和認證業。

中藥測試和認證可帶來很多好處：

- ✔ **對中藥使用者**—可讓他們辨別產品的真偽、減低他們購入一些造假、處理不當(例如漂白)、摻雜其他成份或受污染等產品的機會。
- ✔ **對中藥生產商及貿易商**—有助加強顧客的信心及滿意程度，增加產品的銷量，及減低產品因不達有關中藥規管的法例要求而須回收及招致訴訟。
- ✔ **對中醫師**—可確保他們使用的中藥是真的及具質量保證。
- ✔ **對香港**—可促進檢測和認證業進一步的發展，以及鞏固香港作為一個中藥檢測和認證中心的地位。長遠而言，有助保持香港經濟的發展。

Hong Kong is an International trading hub of Chinese medicines with import and re-export amounting to HK\$2 billion and HK\$860 million respectively in 2010. Chinese herbal medicines and proprietary Chinese medicines (pCm) sold in Hong Kong are generally with good quality. To ensure that products are genuine and not misprocessed (such as bleached), and are free from adulteration and contamination, testing and certification is an important means. Hong Kong is fortunate to have an efficient and technologically sound testing and certification industry.

Testing and certification of Chinese medicines can bring about many benefits to:

- ✔ **Users:** It can help users to identify genuine products, reduces the chance of buying fake, misprocessed (such as bleached), adulterated or contaminated products.
- ✔ **Manufacturers and Traders:** It can help enhance customer confidence and satisfaction, increase sales, and reduce the risk of costly recalls and lawsuits.
- ✔ **Chinese Medicine Practitioners:** It can ensure that prescriptions are filled with genuine and quality medicinal herbs.
- ✔ **Hong Kong:** It can promote the further development of the testing and certification industry and reinforce the position and strategic advantage of Hong Kong as a testing and certification hub of Chinese medicines. This in turn will sustain the economic growth of Hong Kong in the long run.



中成藥測試 Proprietary Chinese medicines testing

根據《中醫藥條例》(香港法例第549章)，自2003年起中成藥在註冊時須進行重金屬及有毒元素含量、農藥殘留量及微生物限度等安全性測試，以証明符合有關的安全要求。詳情請瀏覽香港中醫藥管理委員會網頁 www.cmchk.org.hk

Under the Chinese Medicine Ordinance (Chapter 549 of the Laws of Hong Kong), testing for heavy metals, toxic elements, pesticide residues and microbial limits has been required for the registration of pCm since 2003 to ensure that they can meet the safety requirements. For more details, please visit the website of the Chinese Medicine Council of Hong Kong www.cmchk.org.hk



中藥材測試 Chinese materia medica testing

現時，很多中藥材可按《香港中藥材標準》或《中國藥典》等標準進行測試。《香港中藥材標準》為相關中藥材在安全及品質測試方面，提供了一套標準，對中藥測試非常重要。由於中藥材是中成藥的原材料，測試有助確保相關中成藥的質量。衛生署發展的《香港中藥材標準》將於2012年底涵蓋200種香港常用的中藥材。

Many types of Chinese medicines can now be tested against the Hong Kong Chinese Materia Medica Standards (HKCMMS) or the Pharmacopoeia of the People's Republic of China (PRC). The HKCMMS is of great importance because it can provide relevant standards for safety and quality testing of Chinese materia medica. As Chinese materia medica are raw materials for pCm, the testing could help to ensure the quality of the pCm concerned. The Department of Health has developed HKCMMS which will cover 200 types of Chinese materia medica commonly used in Hong Kong by late 2012.



香港實驗所提供的中藥測試包括： Chinese Medicines Testing Services Provided by Laboratories in Hong Kong include:

中成藥 Proprietary Chinese Medicines

安全測試 Safety testing

- ✔ 重金屬及有毒元素 Heavy metals and toxic elements
- ✔ 農藥殘留 Pesticide residues
- ✔ 微生物檢查 Microbiological examinations

品質及其他測試 Quality and other testing

- ✔ 品質標準化驗 Analysis to product specifications
- ✔ 穩定性試驗 Stability
- ✔ 按《中國藥典》進行的其他測試
如：水份、重量差異、裝量差異及崩解時限
Other testing according to the Pharmacopoeia of PRC
e.g. water, weight variation, filling variation and disintegration



中藥材 Chinese Materia Medica

真偽測試 Authentication

- ✔ 透過外觀、顯微鑒別及理化測試以判斷真偽
Authentication by visual examination, microscopic identification and physicochemical testing

安全測試 Safety testing

- ✔ 重金屬及有毒元素 Heavy metals and toxic elements
- ✔ 農藥殘留 Pesticide residues
- ✔ 黃曲霉毒素 Aflatoxins

品質及其他測試 Quality and other testing

- ✔ 按《香港中藥材標準》或《中國藥典》進行的品質測試
如：含量測定、灰分、水份及浸出物
Testing according to the HKCMMS or the Pharmacopoeia of PRC for quality
e.g. assay, ash, water content and extractives



實驗所的認可 Accreditation of Laboratories

實驗所的認可是一個重要過程，確保有關測試完全符合香港或國際標準，以及有關測試結果被承認。香港認可處是一個政府的認可機構。獲香港認可處認可的實驗所的技术能力達到有關標準，例如ISO/IEC17025。

香港中醫藥管理委員會接納獲認可實驗所發出的測試報告。

Laboratory accreditation is an important process to ensure that tests are in compliance with Hong Kong or International standards and the test results are recognized. Laboratories accredited by the government accreditation body, the Hong Kong Accreditation Service (HKAS), have achieved the technical competence to meet standards such as ISO/IEC 17025.

Endorsed test reports from HKAS accredited laboratories are accepted by the Chinese Medicine Council of Hong Kong.



香港認可處認可標誌 The HKAS Accreditation Symbol

由香港認可處認可實驗所發出的認可測試報告/證書均具備認可處的標誌，並註明獲認可實驗所的登記編號。認可處標誌可作為一個合適的指標，反映相關獲認可實驗所測試產品的質量。

Endorsed test reports/certificates issued by HKAS accredited laboratories bear the HKAS accreditation symbol and the registration number of the accredited laboratories. The HKAS accreditation symbol can be regarded as a good indication of the quality of the product tested by the accredited laboratories.



獲香港認可處認可的中藥測試實驗室 (截至2012年7月)
Laboratories accredited by HKAS providing testing services on Chinese medicines (As at July 2012)

下列機構為公眾提供一項或多項獲認可的中藥測試服務：

The organisations below can provide the public with one or several types of accredited Chinese medicines testing services :

| | |
|--|-----------|
| ALS Technichem (HK) Pty Ltd | 2810 1044 |
| 立德國際公證香港有限公司 Bureau Veritas Hong Kong Ltd | 2331 0888 |
| 佳力高試驗中心有限公司 Castco Testing Centre Ltd | 2877 2032 |
| 廠商會檢定中心 CMA Testing and Certification Laboratories | 2898 8198 |
| 歐化藥業有限公司—品質控制實驗室 Europharm Laboratories Company Ltd - QC Laboratory | 2662 2433 |
| 香港生產力促進局—環境及產品創新化驗室 Hong Kong Productivity Council - Environment and Product Innovation Laboratory | 2788 5807 |
| 浸大中醫藥研究有限公司 Institute for the Advancement of Chinese Medicine (IACM) Ltd | 3411 5308 |
| 天祥公證行有限公司 Intertek Testing Services Hong Kong Ltd | 2173 8888 |
| 香港通用公證行有限公司 SGS Hong Kong Ltd | 2334 4481 |
| 香港標準及檢定中心有限公司 The Hong Kong Standards and Testing Centre Ltd | 2666 1888 |
| 匯力實驗室有限公司 Wellab Ltd | 2898 7388 |

詳情及最新資料請瀏覽香港認可處網頁
(www.hkas.gov.hk) 或向有關測試機構查詢。

For details and updated information, please visit the HKAS website
(www.hkas.gov.hk) or contact the testing organisations directly.



香港檢測和認證局
The Hong Kong Council for Testing and Certification

香港檢測和認證局於2009年9月成立，就檢測和認證業的整體發展策略向政府提供意見。該局的願景是發展檢測和認證業的潛力，使「香港檢測·香港認證」的品牌與品質同義，成為信心的商標。

該局選定中藥為檢測和認證服務具潛力發展的領域，並成立推動中藥行業檢測和認證服務小組，監督以下事宜：

- (i) 發展新的中藥檢測認證服務；
- (ii) 加強實驗室技術能力；及
- (iii) 推廣及宣傳香港的中藥產品檢測和認證服務

透過本港的研發機構、大學和專業人才，我們會為檢測和認證業帶來更多商機，並加強香港作為中藥國際貿易中心的地位。

The Hong Kong Council for Testing and Certification was set up in September 2009 to advise the Government on the overall development strategy of the testing and certification industry. The vision is to develop the potentials of the industry, so "Tested in Hong Kong, Certified in Hong Kong" will be synonymous to quality, and a mark for confidence.

Chinese medicines have been identified as an area with good potential for development. A panel was set up to oversee the following :

- (i) Development of new Chinese medicines testing and certification services;
- (ii) Enhancement of the technical capability of laboratories; and
- (iii) Promotion of Hong Kong's testing and certification services for Chinese medicines products

Tapping the resources from our research and development institutions, universities and committed workforce, we would bring more business opportunities to the testing and certification industry and would strengthen Hong Kong's position as an International trading centre for Chinese medicines.

推動中藥行業檢測和認證服務小組舉辦的活動

Activities organised by the Panel on Promoting Testing and Certification Services in Chinese Medicines Trade.



顯微鏡辨別課程
Microscopic Identification Courses



研討會
Seminar

如要了解詳情，請瀏覽以下網頁
For more information, please visit the following websites

香港檢測和認證局
Hong Kong Council for Testing and Certification
www.hkctc.gov.hk

香港認可處
Hong Kong Accreditation Service
www.hkas.gov.hk

2012年8月
August 2012

香港檢測和認證局印製
Published by the Hong Kong Council for Testing and Certification

香港檢測·香港認證
Tested in Hong Kong
Certified in Hong Kong

中藥測試
Chinese
Medicines
Testing



主辦機構 Organiser

中藥研究及發展委員會
Committee on Research and
Development of Chinese Medicines

合辦機構 Co-organisers



衛生署
Department of Health



醫院管理局
HOSPITAL
AUTHORITY

香港檢測和認證局
Hong Kong Council for
Testing and Certification

支持機構 Supporting Organisation



Hong Kong 香港科技園
Science & Technology Parks



中藥研討會 Seminar on Chinese Medicines

2012年9月14日 (星期五)
14 September 2012 (Friday)

上午9時至下午5時30分
9:00 am to 5:30 pm



香港新界沙田白石角香港科學園
科技大道西十號高錕會議中心

Charles K. Kao Auditorium
10 Hong Kong Science Park West Avenue
Hong Kong Science Park, Pak Shek Kok
Shatin, New Territories, Hong Kong

研討會語言：
廣東話、普通話及英語
(設即時傳譯服務)

Seminar Languages:
Cantonese, Putonghua and English
(with simultaneous interpretation service)

研討會程序 Seminar Programme

| 時間 Time | 程序 Programme |
|------------|---|
| 9:00 am | 登記 Registration |
| 9:30 am | 歡迎辭 Welcoming Remarks 中藥研究及發展委員會主席暨創新科技署署長王榮珍女士 Miss Janet WONG, Chairperson, Committee on Research and Development of Chinese Medicines and Commissioner for Innovation and Technology 衛生署署長陳漢儀醫生 Dr. Constance CHAN, Director of Health, Department of Health 醫院管理局策略發展總監羅思偉醫生 Dr. LO Su-vui, Director (Strategy & Planning), Hospital Authority |
| 9:40 am | 香港中藥規管的最新情況 Development of regulatory regime for Chinese medicines in Hong Kong – the latest update 衛生署助理署長(中醫藥)林文健醫生 Dr. Ronald LAM, Assistant Director (Traditional Chinese Medicine), Department of Health |
| 10:00 am | 中西醫藥結合研究 Integrative medicine 香港中文大學校長沈祖堯教授 Prof. Joseph SUNG, Vice-Chancellor and President, The Chinese University of Hong Kong |
| 10:20 am | 如何協助現代化中藥由實驗室走進臨床 – 以枸杞子作為例子 Bringing modernised Chinese medicines from bench side to bed side, using Gouqizi as an example 香港大學李嘉誠醫學院解剖學系講座教授，何馮月燕基金教授(神經科學)蘇國輝教授 Prof. SO Kwok-fai, Jessie Ho Professorship in Neuroscience, and Chair Professor, Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong |
| 10:40 am | 國家的中醫藥研究 Chinese medicine R&D in the Mainland 香港浸會大學中醫藥學院院長呂愛平教授 Prof. LU Aiping, Dean, School of Chinese Medicine, Hong Kong Baptist University |
| 11:00 am | 發展中藥第一期臨床研究中心的挑戰 The challenge of developing Phase I Clinical Trial Center for Chinese medicines 中國中醫科學院西苑醫院院長唐旭東教授 Prof. TANG Xudong, Director, Xi Yuan Hospital of China Academy of Chinese Medical Sciences |
| 11:20 am | 小休及茶點 Tea Break |
| 11:40 am | 集成多種前沿技術，研究中藥質量及篩選創新藥物 Synthesizing multiple cutting-age technologies for quality research of Chinese medicines and innovative drug screening 澳門科技大學副校長劉良教授 Prof. LIU Liang, Vice Rector, Macau University of Science and Technology |
| 12:00 noon | 醫院管理局在中醫藥方面的工作 The work of the Hospital Authority relating to Chinese medicine 香港醫院管理局中醫及中西醫結合服務主管謝達之博士 Dr. Eric ZIEA, Chief (Chinese Medicine and Integrative Medicine), Hospital Authority |

研討會程序 Seminar Programme

| 時間 Time | 程序 Programme |
|----------|---|
| 12:20 pm | <p>創新中藥研發中企業與科研機構合作的優勢探討 The benefits of industry-academia collaboration in R&D of innovative TCM products</p> <p>賽諾菲公司亞太研發中心中藥研發副總監郭若玲博士 Dr. GUO Ruoling, Associate Director, TCM Lead, Asia Pacific R&D, Sanofi</p> |
| 12:40 pm | <p>香港的中藥檢測和認證情況 Testing and certification of Chinese medicines in Hong Kong</p> <p>香港檢測和認證局成員林俊康先生 Mr. Dominic LAM, Member, Hong Kong Council for Testing and Certification</p> |
| 1:00 pm | <p>交流及午膳 Networking and Lunch</p> <p>主題 : 中草藥 Theme : Chinese Herbal Medicine</p> |
| 2:30 pm | <p>主持 : 香港中文大學中醫學院梁榮能院長 Chair : Prof. Albert LEUNG, Director, School of Chinese Medicine, The Chinese University of Hong Kong</p> |
| 2:35 pm | <p>傳統中藥複方治療常見慢性疾病的系統評價 Systematic review of traditional herbal formulae for the treatment of common chronic diseases</p> <p>香港浸會大學中醫藥學院(教學部)助理教授徐敏博士 Dr. XU Min, Assistant Professor (Teaching Division), School of Chinese Medicine, Hong Kong Baptist University</p> |
| 2:50 pm | <p>基於循證的中醫預防與治療乙型肝炎及其併發症：機遇與挑戰 Evidence based management of HBV and its liver complications using Chinese herbal medicine: Challenges ahead</p> <p>香港浸會大學中醫藥學院副院長及臨床部主任卞兆祥教授 Prof. BIAN Zhao-xiang, Associate Dean and Director of Clinical Division, School of Chinese Medicine, Hong Kong Baptist University</p> |
| 3:05 pm | <p>中藥抗肝纖維化的效果：系統回顧和對隨機對照試驗的整合分析 Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials</p> <p>香港大學中醫藥學院助理院長(教學)馮奕斌博士 Dr. FENG Yi-bin, Assistant Director (Education), School of Chinese Medicine, The University of Hong Kong</p> |
| 3:20 pm | <p>小休及茶點 Tea Break</p> <p>主題 : 針灸 Theme : Acupuncture</p> |
| 3:40 pm | <p>主持 : 香港浸會大學中醫藥學院呂愛平院長 Chair : Prof. LU Aiping, Dean, School of Chinese Medicine, Hong Kong Baptist University</p> |
| 3:45 pm | <p>針灸與中藥預防及治療失眠 Prevention and treatment for insomnia using acupuncture and/or Chinese herbal medicine</p> <p>香港大學精神醫學系臨床副教授鍾家輝醫生 Dr. CHUNG Ka-fai, Clinical Associate Professor, Department of Psychiatry, The University of Hong Kong</p> |

研討會程序 Seminar Programme

| 時間 Time | 程序 Programme |
|--|---|
| 4:00 pm | <p>系統回顧研究 -- 中醫藥和針灸對肥胖的治療作用 A systematic review on use of Chinese medicine and acupuncture for treatment of obesity</p> <p>亞洲糖尿病基金會助理研究員隋昶博士 Dr. SUI Yi, Research Associate, Asia Diabetes Foundation</p> |
| 4:15 pm | <p>密集顱部電針刺激用於神經精神疾患：原理和臨床應用 Dense cranial electroacupuncture stimulation for neuropsychiatric disorders: rationale and clinical application</p> <p>香港大學中醫藥學院助理院長(臨床)張樟進博士 Dr. ZHANG Zhang-jin, Assistant Director (Clinical Affairs), School of Chinese Medicine, The University of Hong Kong</p> |
| <p>主題：中西藥相互作用、氣功及太極、臨床試驗 Theme: Herb-Drug interaction, Qi-Gong and Taichi, Clinical Trial</p> | |
| 4:30 pm | <p>主持：香港大學中醫藥學院童瑤院長 Chair: Prof. TONG Yao, Director, School of Chinese Medicine, The University of Hong Kong</p> |
| 4:35 pm | <p>特敏福與中藥方劑交互作用的研究 Studies of herb-drug interaction involving Oseltamivir and Chinese medicine formulae</p> <p>香港中文大學藥劑學院左中教授 Prof. Joan ZUO, School of Pharmacy, The Chinese University of Hong Kong</p> |
| 4:50 pm | <p>中國氣功在疾病預防及復康中的應用 Use of Chinese Qi-Gong in prevention and rehabilitation</p> <p>香港大學行為健康教研中心陳麗雲教授 Prof. Cecilia CHAN, Centre on Behavioral Health, The University of Hong Kong</p> |
| 5:05 pm | <p>從病人角度評價中醫療效 Evaluating effectiveness of Chinese medicine treatment from patients' perspective</p> <p>香港中文大學賽馬會公共衛生及基層醫療學院助理教授鍾志豪博士 Dr. Vincent CHUNG, Assistant Professor, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong</p> |
| 5:20 pm | <p>閉幕辭 Closing Remarks</p> <p>中藥研究及發展委員會主席暨創新科技署署長王榮珍女士 Miss Janet WONG, Chairperson, Committee on Research and Development of Chinese Medicines and Commissioner for Innovation and Technology</p> |
| <p>研討會結束 End of the Seminar</p> | |

主辦機構保留調動研討會題目，內容及講者的權利而不預先通知。

The Organiser reserves the right to alter the topic/content/speaker of the seminar programme without prior notice.

中藥現代化 結合傳統與創新

世界各地對中醫藥的認受性日益提高，漸成為現代醫學的重要部分。近年政府致力推動中醫藥發展，中藥研究及發展委員會早前舉辦了「中藥研討會」，與業界分享最新的中藥研發項目及成果，冀帶動香港中醫藥走向國際化。



研討會邀請多位來自官、產、學、研各界的專家和學者出席，探討本地中藥規管機制、臨床試驗、研發合作等多項議題。

研討會邀請多位來自官、產、學、研各界的專家和學者出席，探討本地中藥規管機制、臨床試驗、研發合作等多項議題。香港科技大學理學院院長葉玉如教授亦指出，本港健全的法律保障、完善的管理制度、良好的檢測認證聲譽，及達國際水平的科研能力等，均為中醫藥現代化發展提供優越的客觀條件。

善用科研優勢 促進中藥現代化

中藥現代化的扼要是利用現代科學方法闡明中藥的作用、目的和機理，提高藥物品質。香港大學中醫藥學院院長童瑤教授指出，日新月異的科技對推動中藥現代化發展有很大幫助，「具體要達到品質標準化，藥材要安全、有效、穩定；



葉玉如教授表示，政府可鼓勵跨領域科研合作，加強與內地和國際交流，提升本港中藥科研水平。

另外是療效數據化，用循證醫學方法說明中藥療效；最後是劑型精品化，加強中藥複方成分的分析和研究，着重中藥炮製原理，推行劑型改革。」

葉教授舉例說，她的研究團隊早前在分析不同的中藥與腦神經功能作用的研究中，發現一種能增強學習記憶能力的物質，盼能以此為基礎研發新一代醫治腦退化症藥物，為此類疾病患者帶來希望。港大中醫藥學院亦發現，針灸對治療抑鬱症的效果比傳統抗抑鬱藥物更具優勢。憑藉本港的科研優勢，香港可乘內地大力發展中醫藥的機遇下受惠，雙方互

相合作和借鑒，共同發展。呂教授指出，中藥的研發最重要是弄清楚藥物的成分和機理，「研發可朝兩個方向，一是基於中藥有效成分的研發，確保藥物的成分清楚和機理清楚，二是研製優質的複方中藥和保健品，突出中醫藥理論和治療優勢；並藉此推向國際，成為世界通用藥。」

中藥產業蘊藏龐大的發展潛力，本港應發揮既有優勢，進一步提升中醫藥服務。香港浸會大學中醫藥學院院長呂愛平教授表示，香港人才高度集中，且國際化的環境較易吸引人才來港工作，有助推動中醫藥業界發展。香港科技大學理學院院長葉玉如教授亦指出，本港健全的法律保障、完善的管理制度、良好的檢測認證聲譽，及達國際水平的科研能力等，均為中醫藥現代化發展提供優越的客觀條件。

培育跨領域人才 鼓勵跨學科合作

現代中醫藥科研涉及多學科知識，要培育優秀人才，葉教授與童教授不約而同地表示，院校可進行跨學科合作，更全面地推動中醫藥研究發展。葉教授說：「中藥研究所涉及的學術領域甚廣，包括化學、生物、現代醫學及傳統中醫藥理論等。若要把新的中藥產品打進市場，市場學的人才亦擔當重要角色。把不同領域的人才匯聚，互相交流，因應問題作出針對性的研究，方可對整體情況有全面深入的了解。本地院校應加強與海外機構合作，使國際社會對中醫藥有更深入的認識，這樣才能容易推動中醫藥走向國際化。」

童教授認為，中西醫藥結合治療是國際趨勢，而香港在東、西方文化交流的優勢下，絕對是發展中西醫藥結合的理想地。「來港工作多年，親眼看見中西醫從互相觸碰到現時共同合作開展研究。本港三所大學的中醫藥學院為業界不斷培育既掌握中醫藥專業知識，又認識現代生命科學概念的現代中醫藥人才，為中西醫藥深入合作奠定基礎。」

加強官產學研合作

政府近年積極推動中藥檢測和認證，不但提升市民使用中藥的信心，亦有助業界長遠發展。呂教授表示，除了鑑別中藥材的真偽，也要對來源地、生產過程等進行質量控制和安全性檢定，確保中藥的品質，為業界建立良好信譽。「浸大於二〇一〇年成立香港中藥檢定中心，為中藥產品提供一條龍的檢定服務，確保重金屬、農藥殘餘及微生物等各方面符合法定標準。政府應該進一步加強中藥檢定工作，促進香港成為中藥檢定的國際中心地位。」

葉教授認為，中醫藥發展須要政府、業界及學界三方面的緊密合作，支援科研、質控、臨床循證醫學研究和應用，「三者應保持密切的合作關係：政府資助科研項目，提供硬件配套，並可擔當統籌角色；業界支持政府推行中醫藥相關政策和措施，與學界合作進行中醫



中藥研究及發展委員會主席監創科技署署長王榮珍(中)、衛生署署長陳漢儀醫生(右五)、醫院管理局策略發展總監羅恩偉醫生(左五)和香港中文大學校長沈祖堯教授(右四)在中藥研討會上與一眾嘉賓講者合照。



呂愛平教授指出，應善用香港優勢把中醫藥做到國際化、標準化及將現代科技與中西醫藥結合。



童瑤教授認為，香港具有獨特的中西文化背景，可擔當中醫藥國際化橋樑。

藥研究；學界可提供專業知識和技術予業界和政府。」童教授強調要發揮中醫藥的最大優勢，中醫中藥不能分離，中藥研究不應忽略傳統中醫理論及辨證論治的方法。她亦建議可把中醫正式納入醫療服務體系，「中醫地位提高了，才可真正促進中藥業的發展，提高中藥品質及管理水平。」

00A20 28/9

官產學研積極推動

中藥業走向國際化

中藥業近十年持續發展，政府也大力推動，創新科技署於2011年12月成立中藥研究及發展委員會（委員會）協調各界持份者，包括政府部門、公營機構、業界和學術界，共同推動香港中藥研發和檢測的發展。早前，委員會於沙田科學園舉辦了為期一天的中藥研討會，讓來自官、產、學、研各界逾四百名人士聚首一堂，共同探討中醫藥研究的最新發展。

香港中藥業人才濟濟，位元堂執行董事鄧梅芬、香港中藥業協會創會會長兼理事長李應生和余仁生（香港）董事總經理黃雪英均是委員會成員，就發展香港中藥業，從業界的角度提供寶貴意見。

推行 GMP 有助中藥業發展

隨着時代轉變，中藥業正走向現代化發展。位元堂執行董事鄧梅芬說：「談及中藥，以前只會聯想到煲藥，至十年前，我們從製作藥粉黏成的蜜丸，現今已發展到生產沖劑等，利用現代化的技術、用最有效的成分來提煉出沖劑、顆粒等成品，改良了中藥，使其更為方便、有效。」

鄧梅芬表示，支持中藥現代化發展是大趨勢，要令中藥界趨向國際化，推行中藥註冊制度及中成藥製造商要具備「中成藥生產質量管理規範」（GMP）認證等都是十分重要的措施。她說：「中藥現代化的進程亦包括安全性、效用及品質檢測的數據化和科學化，以提高中藥的市場認受性，這樣中藥界才可跨出香港，邁向國際。」現時，本地近三百間藥廠中僅九間擁有香港中成藥 GMP 證書，鄧梅芬認為，政府可進一步推動 GMP 普及化。此外，鄧梅芬亦希望大學可與業界多些溝通、合作，把大學研究成果商品化、推出市場，這樣市民也會得益。鄧梅芬指出，「香港製造」的品牌是香港中藥業的優勢，冀政府、大學和業界能攜手促進科研成果產業化，培養更多人才。



位元堂執行董事鄧梅芬冀政府可進一步推動 GMP 普及化。



香港中藥業協會創會會長兼理事長李應生認為，發展中藥認證可進一步增強市民服用中藥的信心。

發展中藥認證 增市民信心

香港中藥業協會創會會長兼理事長李應生認為：「現今的中藥業已不能停留在主觀的傳統概念，而是要有客觀的科學根據和研究數據以證明產品安全有效。

要得到市民信賴和國際認可，必須透過科研引證中藥的成分；中藥的研發、檢測和認證發展對業界開拓海外市場尤其重要。」

李應生舉例說，現時，中藥飲片種類繁多，中藥材來自各個不同產地，也有容易被混淆的藥材品種。認證機構可認證中藥飲片已達到其成分指標，以及沒有重金屬和農藥殘留，以證明其安全可靠，對產品出口至海外市場有很大幫助。此外，發展中成藥認證，亦可進一步增強市民對服用中成藥的信心。

李應生期望政府可以透過創新科技署負責的中藥研究及發展委員會和由食物及衛生局局長籌組的中醫藥發展委員會，就中藥發展事宜向各界持份者，包括公營機構、業界和大學收集意見，並統籌香港中藥科研、檢測的發展方向。李應生表示：「香港的中藥業很具優勢，信譽好、監管強、產品優質、完善的認可制度和國際網絡，更不設出入口關稅，實在甚具發展潛力。」

業界與大學加強科研合作

對於中藥業的發展，官、產、學、研的互動起着關鍵作用。余仁生（香港）董事總經理黃雪英說：「中藥現代化在香港發展至今已十多年，期間政府對中醫、中藥作出規管，推動業界做得更好。業界方面也開始推行 GMP 認證，大學亦培訓出不少中醫、中藥界人才，社會整體上對業界的認受性較十多年前已提高了很多。」

另一方面，黃雪英認為要增加國際對中醫中藥的信心就必須使用科學的數據去印證。近年，政府、業界與大學在不同層面都在科研方面做了不少工作。以余仁生為例，公司早年曾與中文大學合作研究金牌白鳳丸的藥理機制及開發中成藥，並資助浸會大學進行治療帕金森症的臨床研究，另外亦進行多項中藥材飲片及中成藥的研究項目，致力推廣中藥科學化，從而把中成藥產品推廣至國際市場。她認為，未來香港中藥界亦應重點發展科研、檢測及認證，讓業界在開發、製造及銷售此類產品時有標準可依循，此舉亦可進一步增強消費者對香港中藥產品的信心。

黃雪英說，經過多年來各方面的努力，現時香港中成藥的認受性已逐漸提高，「香港製造」的品牌是質素保證，希望未來官、產、學、研能結合力量，令中藥業有更好的發展，將來不論任何國籍人士只要想起良好的中藥產品，便會即時想起香港製造。



余仁生（香港）董事總經理黃雪英表示，「香港製造」的品牌是質素保證，業界應好好發展。



資料：由客戶提供

香港科技園公司 支持香港中藥業發展

香港科技園公司（科技園公司）自2001年起負責管理香港科學園，並一直致力為以研發科技為本的公司提供一站式服務，透過推動五大領域，當中包括生物科技，支援本地科技的發展。而生物科技涵蓋的範疇甚廣，中藥及西藥業是較為人所熟悉的。現時沙田科學園內已有十家從事中藥研究的公司。

科技園公司行政總裁陳蔭楠是委員會的其中一名當然成員。他說：「科學園不但提供硬件設施，如共用實驗室，亦配合不同服務，協助進駐的公司減省開發的成本。科學園第二期的生物科技中心，分兩座實驗室大樓予專門從事生命科學領域的公司使用。中心內除擁有實驗室儀器外，我們更有技術人員作出支援。」

此外，科技園公司設立為期四年的「生物科技創業培育計劃」，為新晉生物科技公司提供辦公室及多項支援服務，例如商業配對服務、培訓課程、法律顧問服務、業務計劃顧問服務及租金和資金津貼等。另外，亦不時舉辦研討會及會議，介紹生物科技、中醫藥及檢測和認證等最新的科技及市場資訊，協助業界進一步了解中醫藥的發展。這些支援對從事中藥研發的新晉公司有很大的幫助。」

除吸納有興趣的公司進駐科學園外，科技園公司更在大埔、元朗和將軍澳工業邨為中藥製造業提供合適土地，陳蔭楠續說：「現時，工業邨內共有九間中藥廠，例如位於元朗工業邨內的余仁生、念慈菴等。」展望未來，陳蔭楠希望科技園公司提供的設施及服務能持續提升，協助改進中藥公司生產水平，以符合市場需求，尤其要達到 GMP 的要求。另外，香港的中藥檢測和認證服務甚具水準，在國際獲得肯定。香港作為一個國際化的城市，是一個很好的開發基地，從而將中藥帶到國際。因此，香港中藥業的未來發展，極具優勢。



科技園公司行政總裁陳蔭楠指出，科技園公司推出培育計劃，協助業界進一步發展。